Status:
COMPLETED
Anticoagulant/Antiaggregant Use and Postoperative Bleeding Risk in Patients With Bladder Tumor and Benign Prostatic Hyperplasia
Lead Sponsor:
Bezmialem Vakif University
Conditions:
Hematuria
Retention, Urinary
Eligibility:
All Genders
Brief Summary
Patients who were using anticoagulant or antiaggregant medications for any reason and underwent transurethral resection of bladder tumor (TUR-BT) or transurethral resection of the prostate (TURP) or o...
Eligibility Criteria
Inclusion
- Patients undergoing complete endoscopic transurethral tumor resection (TUR-BT) for bladder cancer
- Patients undergoing TURP due to benign prostatic hyperplasia
- Patients undergoing open prostatectomy due to benign prostatic hyperplasia
Exclusion
- Patients who underwent incomplete transurethral tumor resection for bladder cancer
- Patient who underwent TUR biopsy for restaging with no obvious macroscopic tumoral lesion
- Patients who underwent cystectomy for bladder cancer
Key Trial Info
Start Date :
March 10 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 10 2023
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT05314582
Start Date
March 10 2022
End Date
January 10 2023
Last Update
July 28 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bezmialem Vakif University
Istanbul, Turkey (Türkiye), 34093